Saxenda^® (liraglutide) injection 3 mg is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m² or greater (obesity) or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition (eg, hypertension, type 2 diabetes mellitus, or dyslipidemia)

Anti-obesity medication coverage is different from what you may be used to; an employer decides whether or not to opt-in to add the additional coverage to its base plan. Please fill out the form below to see if you are covered.  If additional information is required, our office will contact you.

Saxenda^® is a registered trademark of Novo Nordisk A/S.